CRL Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
1.0B
+0.8%
995.8M
+0.2%
994.2M
-1.1%
1.0B
-2.6%
1.0B
Cost of Revenue
640.7M
-8.6%
701.2M
+2.4%
684.5M
+2.8%
666.1M
-1.3%
675.1M
Gross Profit
363.4M
+23.3%
294.7M
-4.9%
309.7M
-8.6%
338.8M
-5.1%
357.1M
Operating Expenses
243.5M
+39.3%
174.8M
-70.5%
593.1M
+189.3%
205.0M
-20.2%
256.9M
R&D
0
0
0
0
0
SG&A
228.9M
+43.6%
159.4M
-18.7%
196.1M
+10.4%
177.6M
-7.3%
191.5M
Operating Income
119.9M
-0.0%
119.9M
+142.3%
-283440000
-311.8%
133.8M
+33.6%
100.1M
EBITDA
187.2M
+0.1%
187.0M
+9.5%
170.8M
-22.0%
219.0M
-0.3%
219.6M
Net Income
-760000
+94.9%
-14802000
+94.6%
-276290000
-597.3%
55.6M
+5.4%
52.7M
EPS (Basic)
$-0.03
+90.0%
$-0.30
+94.7%
$-5.62
-606.3%
$1.11
+4.7%
$1.06
EPS (Diluted)
$-0.03
+90.0%
$-0.30
+94.7%
$-5.68
-616.4%
$1.10
+3.8%
$1.06
Shares (Diluted)
48.0M
-1.9%
49.0M
+0.6%
48.7M
-1.5%
49.4M
+0.2%
49.3M
Charles River Laboratories International (CRL) โ€” Financials